Plus   Neg

Novartis Issues Update On Its R&D Pipeline - Quick Facts

At the R&D Day, Novartis AG (NVS) stated that approximately 90 innovative new molecular entities are emerging from the Novartis Institutes for BioMedical Research. Novartis said the company has established leadership in three advanced therapy platforms: cell, gene and radioligand therapies, with a total of 16 advanced platform therapies now in clinical development.

The company is prioritizing emerging assets that address significant unmet need. These include iscalimab in transplant and Sjögren's syndrome, LNP023 in renal diseases and PNH, MBG453 in MDS, and TQJ230 in cardiovascular risk reduction. They will be advanced into pivotal trials in the coming years.

Novartis has 60 projects in phase 2 pipeline with more than 10 advancing into phase 3 or pivotal trials each year in 2020 and 2021. Anticipated near-term launches include ofatumumab in relapsing MS, fevipiprant in asthma, radioligand therapy Lu-PSMA-617 in prostate cancer, Adakveo in sickle cell disease and canakinumab in lung cancer.

The company is exploring over 40 new indications for in-market brands, including up to 7 for Cosentyx alone, and others for Beovu, Piqray and Kisqali.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Marathon Petroleum Corp. (MPC) Wednesday reported a sharp fall in fourth quarter net profit attributable to MPC to $443 million, or $0.68 per share from $951 million, or $1.35 per share last year. Non controlling interests for the quarter was a loss of $201 million, while it recorded a profit of $224... Swiss drug major Novartis AG reported Wednesday that its fourth-quarter net profit declined, while operating income climbed on strong sales growth. Looking ahead, for fiscal 2020, the company expects net sales to grow mid to high-single digit and core operating income to grow high-single to low double digit, both in constant currency. Starbucks on Tuesday said it has closed more than half of its stores in China temporarily due to the worsening coronavirus outbreak that claimed around 132 lives in the country. The coffee giant is also monitoring and modifying the operating hours of all of its stores in the region.The closed store count would be more than 2000 as Starbucks operates almost 4,300 outlets in China.
Follow RTT